Edoxaban + Warfarin + Enoxaparin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Atrial Fibrillation
Conditions
Atrial Fibrillation
Trial Timeline
Mar 25, 2014 → Feb 3, 2016
NCT ID
NCT02072434About Edoxaban + Warfarin + Enoxaparin
Edoxaban + Warfarin + Enoxaparin is a phase 3 stage product being developed by Daiichi Sankyo for Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT02072434. Target conditions include Atrial Fibrillation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02072434 | Phase 3 | Completed |
Competing Products
20 competing products in Atrial Fibrillation